Nostrilla Nasal Decongestant Recalled

News
By published

Insight Pharmaceuticals, LLC of Langhorne, Pa., is recalling one lot (34,092 bottles) of Nostrilla Nasal Decongestant nasal spray to the consumer level, because it may contain the bacteria Burkholderia cepacia.

ISSUE: Insight Pharmaceuticals, LLC recalled one lot (lot #11G075, UPC Code 6373673005, 34,092 bottles) of Nostrilla Nasal Decongestant nasal spray to the consumer level, because it may contain the bacteria Burkholderia cepacia. Burkholderia cepacia may cause serious infection in individuals with a compromised immune system or chronic lung condition (i.e. cystic fibrosis).

BACKGROUND: Nostrilla Nasal Decongestant was distributed nationwide through normal retail outlets and pharmacies. The product comes in a 1/2 ounce, plastic bottle marked with an expiration date of 05/2014 stamped on the side.

The recall was initiated following internal investigations which determined the potential presence of a microbial contaminant that exceeds the product specifications and may consequently result in a subpar product. This contaminant has been found sporadically throughout only the respective manufacturing lot, #11G075.

RECOMMENDATION: Consumers who purchased "Nostrilla Decongestant, lot #11G075" are urged to return the product and contact the company at 1-877-546-9059 Monday through Friday from 9 am-5 pm EST time zone. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this product.

Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:

Burkholderia cepacia may cause serious infection in individuals with a compromised immune system or chronic lung condition (i.e. cystic fibrosis). However, the possibility of infection is remote in healthy individuals.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

It is our commitment to our customers to provide them with products they can rely on as safe and effective for their FDA-approved uses, says Gary R. Downing, CEO of Insight Pharmaceuticals, LLC. Through our standard testing procedures and protocols, we discovered the potential presence of a bacterial contaminant in one lot of Nostrilla, and reported it to the FDA. Consumer safety is our #1 priority, and we'll take all necessary action to ensure Nostrilla, as well as all of our products, comply with FDA regulations and requirements.

Live Science Staff
Live Science Staff
For the science geek in everyone, Live Science offers a fascinating window into the natural and technological world, delivering comprehensive and compelling news and analysis on everything from dinosaur discoveries, archaeological finds and amazing animals to health, innovation and wearable technology. We aim to empower and inspire our readers with the tools needed to understand the world and appreciate its everyday awe.